Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.
Arcutis Biotherapeutics reports company developments as a commercial-stage biopharmaceutical company focused on immuno-dermatology and medical dermatology. Its recurring updates center on ZORYVE (roflumilast) cream and foam, a topical PDE4 inhibitor portfolio used across inflammatory skin diseases including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis.
Company news commonly covers ZORYVE net product revenue, demand trends for branded non-steroidal topical treatments, clinical data from dermatology studies, FDA submissions tied to potential label expansion, medical-meeting presentations, guideline references, sales-force and commercial updates, conference participation, and equity grants made under Nasdaq inducement-grant rules.
Arcutis (Nasdaq: ARQT) announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, held June 8–10, 2026.
A fireside chat is scheduled for Tuesday, June 9, 2026, at 2:00 p.m. ET, with a webcast and 180-day replay on the company website.
Arcutis Biotherapeutics (Nasdaq: ARQT) reported inducement equity grants to 40 newly hired employees under its 2022 Inducement Plan, with a grant date of May 1, 2026.
The company granted 269,000 restricted stock units and options to purchase 70,000 shares. RSUs vest 25% annually over four years. Options vest 25% after one year and monthly over the next three years, have a 10-year term, and an exercise price of $23.35 per share.
Arcutis (Nasdaq: ARQT) reported Q1 2026 results: ZORYVE net product revenue $105.4M (65% YoY, -17% vs Q4 2025). The company generated $2.2M positive operating cash flow, submitted an sNDA for ZORYVE cream 0.05% in infants 3–24 months, and initiated Phase 1 for ARQ-234.
Q1 R&D rose to $30.6M largely due to a $10M Ducentis milestone; net loss was $11.3M. Full-year 2026 revenue guidance: $480M–$495M.
Arcutis (Nasdaq: ARQT) submitted an sNDA to the FDA to expand ZORYVE cream 0.05% (roflumilast) for treatment of mild-to-moderate atopic dermatitis in infants aged ≥3 months to 24 months.The filing is supported by a Phase 1 PK trial (n=19) and the Phase 2 INTEGUMENT-INFANT study (n=101) reporting tolerability and multiple efficacy endpoints, including 34.4% vIGA-AD success at Week 4 and 58.3% EASI-75 at Week 4.
Arcutis (Nasdaq: ARQT) announced that ZORYVE® (roflumilast) cream received a strong recommendation with high certainty in the American Academy of Dermatology pediatric atopic dermatitis guidelines (Apr 22, 2026).
The guidelines recommend ZORYVE 0.05% for ages 2–5 and ZORYVE 0.15% for ages 6 and older, citing clinically meaningful improvements in disease severity and itch and low treatment discontinuation rates.
Arcutis (Nasdaq: ARQT) will report first quarter 2026 financial results and provide a business update on Wednesday, May 6, 2026 after U.S. markets close. The company will host a conference call and webcast the same day at 4:30 PM ET.
A live webcast and presentation materials will be available in the Events section of the company website, with a replay posted on Arcutis investor site after the call.
Arcutis (Nasdaq: ARQT) said its management team will present at the 25th Annual Needham Virtual Healthcare Conference, April 13-16, 2026. The company will host a Fireside Chat on April 14, 2026 at 11:00 AM ET.
According to the company, the live webcast is available in the Events section of its website, and a replay will be accessible for 180 days after the conference.
Arcutis (Nasdaq: ARQT) presented Phase 2 INTEGUMENT-INFANT data showing investigational ZORYVE cream 0.05% reduced signs and symptoms of mild-to-moderate atopic dermatitis in infants 3 months to <24 months over four weeks and was well tolerated.
Key outcomes include vIGA-AD, EASI-75, scalp results, rapid caregiver-reported itch relief, and safety findings consistent with prior pediatric studies.
Arcutis (Nasdaq: ARQT) will present new clinical and long-term caregiver-reported data for its marketed ZORYVE (roflumilast) portfolio at the 2026 American Academy of Dermatology Annual Meeting, March 27–31 in Denver. Key presentations include a late-breaking podium on the INTEGUMENT-INFANT Phase 2 trial (infants 3–<24 months) and Phase 3 subgroup and PASI results from STRATUM, DERMIS-1/2, ARRECTOR, and INTEGUMENT-OLE (ages 2–5).
The program includes a late-breaking podium (Mar 28), a 5-minute poster (Mar 27), and multiple e-posters available beginning Mar 27.
Arcutis (Nasdaq: ARQT) reported long-term Phase 3 open-label extension data for ZORYVE cream 0.05% in children ages 2–5 with mild-to-moderate atopic dermatitis, showing durable and improving efficacy through 56 weeks and a favorable safety/tolerability profile.
Key results: 63.1% achieved vIGA-AD Clear/Almost Clear at Week 56; EASI-75 reached 71.9–76.0% at Week 56; median disease-control duration on twice-weekly proactive dosing ~238 days. Overall TEAEs were mostly mild/moderate; SAEs 3.2% (none treatment-related).